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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A37Results: Of the 351 subjects enrolled in the MeTeOR Trial, 292 had
complete data on outcomes and covariates used in this analysis. 57%
were female and mean age was 58 (SD 7). 141 of these subjects were
randomized to APM and received surgery. Another 93 subjects were
randomized to PT and continued to receive PT, while 58 were
randomized to PT and crossed over to receive APM. Forty percent of
cross-overs occurred within three months of randomization. In multi-
variable analyses, factors associated with a higher likelihood of crossing
over to have APM among those randomized to PT included baseline
WOMAC Pain score > 40 (RR 1.13, 95% CI: 1.05, 1.20), duration of
symptoms less than one year (RR 1.08, 95% CI: 1.01, 1.15) and ability to
extend the knee fully (RR 1.07, 95 % CI: 0.99, 1.16). The model had a c-
statistic of 0.70. The proportion of subjects who achieved a 10 point
improvement in pain score after six months of follow-up ranged from
80% in those randomized to APM, 73% in those randomized to PT who
did not cross over and 69% in subjects who crossed over to APM. In
multivariate analyses, those who crossed over to APM were 23% less
likely to achieve a 10-point improvement in pain score than subjects
originally randomized to APM (RR 0.77 95% CI: 0.54, 0.92), adjusting for
baseline pain and duration of symptoms.
Conclusions: These data suggest that patients assigned to PT who were
most likely to cross over to APM included those with a more acute and
painful onset - characterized by short duration of symptoms, high level
of pain and least extension loss. The ﬁndings also suggest that patients
who cross over to surgery are 23% less likely to experience improve-
ment in pain than those originally randomized to APM. This difference
should be interpreted with care as the groups are not randomized.
Taken together, these ﬁndings suggest a need for 1) further research to
identify patients for whom initial PT is less likely to be successful and 2)
strategies to support patients who do not improve with PT, as the
results of APM in these patients may be worse than in those treated
with APM at the outset.
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Purpose: The goal of this research was to investigate the effects of a
well-known antibiotic, erythromycin, and a well-known “hunger hor-
mone”, ghrelin, on chondrocytes. In recent years, certain macrolide
antibiotics were found to combat inﬂammation in the lung and the
bone, even though they did not affect bacterial growth at the concen-
trations used, suggesting that this activity is independent of its anti-
biotic properties. Among the macrolide antibiotics, only EM has been
tested in one human OA clinical trial, which showed reduction of joint
effusion and pain over the course of 4 months, but how EM achieved
such an effect was not assessed in this study.
Ghrelin is a 28 amino acid long peptide best known as the “hunger
hormone”, since its level is highest before meals and drops after meals.
Ghrelin is reported to have protective effects against pulmonary and
brain injuries in combating inﬂammation and pain. As labeled EM has
been reported to bind to puriﬁed ghrelin receptor, we investigated
whether EM acts through ghrelin receptor on chondrocytes, and
whether ghrelin has a similar activity on chondrocyte gene expression.
Methods: In vitro: Normal human articular chondrocytes (Lonza) or
mouse immature articular chondrocytes were cultured in the presence
or absence of IL-1b, erythromycin and ghrelin (varying amounts) for 4
days followed by RT-PCR. For Western blot analysis of NFkB signaling,
samples were harvested 1hr after IL-1b treatment. In vivo: CD1 mice
were injected either with monosodium iodoacetate (MIA, 62.5mg)
intrarticularly or erythromycin (400 mg) or both, with PBS controls (6/
group). Immunohistochemistry (IHC) was performed 10 days later, and
cartilage damage was quantiﬁed by the OARSI scoring system. Ex vivo:
human OA cartilage slices were cultured in the presence of ghrelin or
PBS for 3 weeks and matrix level was analyzed by IHC and safranin/O
staining. Data are reported as mean ± standard deviation. For para-
metric data, statistical analysis was performed using a one-way analysis
of variance followed by post-hoc Tukey test. For nonparametric data
(OARSI scores), statistical analysis was performed using the Kruskal-
Wallis test followed by Mann-Whitney U test with Bonferroni correc-
tion. P-values of <0.05 were considered signiﬁcant.Results: 1. Erythromycin inhibited IL-1b induced collagen II reduction
and iNOS, MMP1, 3, 9, 13 induction in human chondroctyes (data not
shown), and inhibited IL-1b-induced NFkB nuclear localization (Fig. 1A).
To evaluate the effect of erythromycin on cartilage damage in vivo, we
injected MIA into the knee joint. This model is an OA and pain model
because it demonstrates all features of injury-induced OA, even though
MIA is not present naturally. We found that erythromycin does not
affect cartilage matrix production in normal conditions, but sig-
niﬁcantly reduced MIA-induced matrix loss, even though different
medial-lateral zones have different extent of damage (Fig. 1B and 1C).
2. By utilizing an anti-erythromycin antibody, we found dosage-
dependent binding of erythromycin to mouse articular chondrocytes
after just 3hr or 1 day of erythromycin addition (Fig. 1D). Consistent
with a prior report of erythromycin binding to the ghrelin receptor
GHS-R1, increasing levels of ghrelin administration displaced eryth-
romycin binding to the chondrocytes (data not shown). Furthermore,
such binding was diminished in chondrocytes from the GHS-R KO mice
(Fig. 1E). Correspondingly, erythromycin did not inhibit MMP13
expression in GHS-R KO chondrocytes (Fig. 1F).
3. Ghrelin administration inhibited IL-1b-induced iNOS and MMP
expression in human chondrocytes (data not shown), and this activity
was lost in chondrocytes from GHS-R KO mice (Fig. 1G). Furthermore,
ghrelin inhibited IL-1b-induced NFkB nuclear localization in chon-
drocytes, and increased cartilage matrix levels in human OA cartilage
explant cultures (data not shown).
Conclusions: This work provides a novel link of two molecules that are
not known to regulate chondrocyte gene expression. We show that
erythromycin and ghrelin act through the ghrelin receptor to inhibit
catabolic activities in articular chondrocytes, which may represent a
new mechanism in the control of matrix loss in arthritis.
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